urol.colomb. Vol XX, No. 1: pp. 93-94, 2011 Tolterodine and Tamsulosin for Treatment of Men With Lower Urinary Tract Symptoms and Overactive Bladder (JAMA 2006; 296 (19): 2319-2328) Andrés Felipe Gutiérrez Rojas1, Mauricio Plata Salazar2 M.D., Residente II año de Urología, Pontificia Universidad Javeriana1 M.D., Urólogo, Fundación Santa Fe de Bogotá, maurcioplata@gmail.
Suomen sivusto, jossa voit ostaa halvalla ja laadukas Viagra http://osta-apteekki.com/ toimitus kaikkialle maailmaan.
Erityisesti laatu viagra tästä kaupasta voi taata henkilökohtaisesti levitra Paras laatu kehotan Teitä miellyttää.
Abstracte.pdfAbstracts of the 3rd International Congress on Prediabetes and the Metabolic Syndrome DETERMINATION OF BODY COMPOSITION IN PATIENTS min PG (r=0.7), indicating an inverse relationship between prevailing PG WITH METABOLIC SYNDROME, BY BIO-IMPEDANCE and the presence of edema. Therefore, paradoxically, the risk of BC-L appears to be inversely related to the patients' measured insulin sensitivity. The results are nevertheless strikingly significant, suggesting that further C. Constantin, G. Stan, C. Serafinceanu, D. Cheta investigation of these phenomena will shed insight into the mechanisms of risk. N Paulescu Institute, Bucharest, Romania Introduction: The study of body composition by bio-impedance is a used
method with different devices. The results may influence the therapeutic MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1) IS B. Loughrey1, D. Mc Cance2, I. Young1, L. Powell1 Method: 51 patients (22m/29w) with metabolic syndrome (IDF2005),
admitted in the "N.Paulescu" Institute, were included in this study. Their
1School of Medicine, Dentistry and Biomedical Sciences, mean age was 55.17±10.98years. Their body composition was examined, Queen's University, Belfast, United Kingdom, 2Royal Victoria using next devices: In Body 3.0, Omron BF 500, BCM-Fresenius Medical Care. Weight, BMI, fat-tissue, intra- and extracellular liquid volumes were determined. Data were statistically processed using SPSS 15.0 (T-Student Aim: To evaluate the effect of atorvastatin on serum MCP-1 in people with
Results: As reference the results of In Body3.0 were used, where total body
Methods: 43 subjects with MS (IDF criteria), mean age 49.8 ±7 years (67%
water(TBW) was 42.12±8.38L, distributed as following: 28.21±5.52L male), were compared to 23 lean controls, mean age 46.3 ±7.1 years (57% intracellular body water(IBW) and 13.89±2.98L extracellular body male). Exclusions included: diabetes, statin treatment, and C-reactive protein (CRP) >10 mg/L. MS subjects were randomised to atorvastatin (10 IBW=20.4±4.23L and EBW=17.4±3.26L (p=0.204 for TBW, p=0.441 for mg/day) or placebo for six weeks. Fasting blood was collected for lipid IBW, and p=0.59 for EBW). Results for BMI(kg/m²) were similar: profiles, glucose, hsCRP and serum MCP-1 (High Sensitivity Cytokine 30.41±4.55(In Body) and 30.48±4.55(Omron,p=0.086). Determined weight: 84.2±14.54 kg(In Body) and 84.42±14.56 kg(Omron) (p=0.098). The Results: The metabolic syndrome subjects differed significantly from the
35.14±10.03%(Omron,p=0.0906), 38.29±8.05%(Fresenius,p=0.199), with a lean subjects in the following respects: mean BMI (32.2 vs 23.7 kg/m2, p< 0.001); LDL (3.4 vs 3 mmol/L, p< 0.05); HDL (1.3 vs 1.9 mmol/L, p< 40.82±7.48%(Omron,p=0.271) and 41.6±6.64% (Fresenius,p=0.283, for 0.001); triglycerides (2.1 vs 0.8 mmol/L, p< 0.001); and glucose (5.7 vs 5 women), 27.34±6.69%(In Body), 27.28±7.12%(Omron,p=0.003) and mmol/L, p< 0.001). They also differed in median pre-treatment CRP (2.2 vs 1.0 mg/L, p< 0.001) and MCP-1 (265.8 pg/mL vs 183.9 pg/mL, p< 0.01). Spearman's rank correlation coefficient showed significant correlations between BMI and CRP (p< 0.001), as well as BMI and MCP-1 (p = 0.01), but not between CRP and MCP-1. Neither CRP nor MCP-1 correlated with Conclusions: Under water weighting and DEXA (dual-energy-x-ray
age. Atorvastatin treatment had no significant effect on either CRP or MCP- absorptiometry) are considered to be "gold standard" procedures for 1. There was a small but significant rise in both CRP and MCP-1 in the determining body composition, but they are inaccessible and expensive. As placebo group, which was probably a chance finding. the differences in the results are statistically significant, bio-impedance stands yet approachable alternative in clinical practice, but data could be Conclusion: This study confirms that MCP-1 is elevated alongside CRP in
limited helpful in determining body composition in patients with MS. The obese subjects with the metabolic syndrome. device could influence the behavior in clinical practice. METABOLIC SYNDROME IS ASSOCIATED WITH SILENT DO METABOLIC FACTORS GOVERN THE RISK FOR BREAST H.-M. Kwon1, B.-J. Kim2, Y.-S. Lee1, B.-W. Yoon2 S. Rockson1, I. Wapnir2, C. Chow2, V. Bali1 1Seoul National University Boramae Hospital, Seoul, Korea, 1Stanford University School of Medicine, Division of Republic of, 2Seoul National University Hospital, Seoul, Korea, Cardiovascular Medicine, Stanford, United States of America, 2Stanford University School of Medicine, Department of Surgery, Stanford, United States of America Aims: Metabolic syndrome (MetS) is associated with an increased risk of
the subsequent development of cardiovascular disease or stroke even among
Among the systemic factors associated with lymphedema risk following persons without diabetes. MetS was found to be significantly associated axillary lymph node dissection (ALND), hypertension and obesity have with silent brain infarction (SBI) in neurologically healthy people. been consistently identified. Since insulin resistance (IR) is also associated However, information is scant regarding its relationship of MetS to the SBI with breast cancer-associated lymphedema (BC-L), we studied insulin in nondiabetic adults. Therefore, we conducted a cross-sectional study. sensitivity in 23 breast cancer survivors with and without BC-L. Ratios of limb volume were calculated with the truncated cone approximation. The Methods: We studied 1,029 healthy consecutive elderly subjects aged 65
presence of LE was defined as a ratio>1.1 and was confirmed by measuring who underwent MRI of the brain as part of their routine health check. the bioimpedance ratios (BR) in each patient. 13 patients were BC-L + and Exclusion criteria were as follows: history of a stroke or TIA, history of 10 were BC-L -. The groups were matched for age, BMI and elapsed time diabetes, or taking antidiabetic medications. We examined associations since ALND. Insulin sensitivity was assessed by quantitation of steady state between full syndrome (at least 3 of the 5 conditions) as well as its plasma glucose (SSPG) during octreotide infusion and further confirmed components and SBI by controlling possible confounders. with oral glucose tolerance test (OGTT). Average SSPG values were not significantly different in BC-L + (129±58) vs. BC-L- (168±67) but Results: One hundred fifty subjects (14.6%) were found to have one or
abnormal values >180 were statistically much more frequent in the BCL- more SBI on MRI. Age was found to be significantly related to SBI group (Chi square=7.333, P< 0.007). Plasma glucose (PG) values were prevalence (OR, 1.09; 95% CI, 1.05-1.13). MetS was significantly signficantly higher in BC-L- patients at T=30 and 60 mins, respectively (P< associated with SBI (OR, 2.02; 95% CI, 1.36-2.99). The components model 0.02). There was a strongly positive correlation between the BR and the 60 of MetS showed a strong significance between high blood pressure (OR, 2009 Ruijin Hospital and Blackwell Publishing Asia Pty Ltd
Program Schedule Global Food Science Higher Education Forum Shuixiu Hall (3rd Floor) Session: Dairy Science & Technology (Morning, May 30; Baihe Hall I) Sponsors/Co-organizers: State Key Laboratory of Dairy Biotechnology Moderators: Dr. Stephanie Clark, Iowa State University, USA. Dr. Lloyd Metzger, South Dakota State University, USA. Titles/Speakers: Presentation Titl